1) This certificate denotes compliance with the Poison Prevention Packaging Act (16 CFR § 1700) and the Consumer Product Safety Improvement Act (CPSIA) of 2008 (16 CFR § 1110) as regulated by the US Consumer Product Safety Commission (CPSC).

2) For applicable Date of Manufacture, provide lot number printed on the packaging when making inquiry.

3) Contact Information:

   - Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
   - Genentech Resource Center Phone: 1-877-436-3683

4) Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080 is the importer for all products packaged outside the US.

5) F. Hoffmann-La Roche Ltd., CH-4070 Basel packaged all product into the respective child resistant closure / containers.

6) Reference the Electronic Controlled Content Management (ECCM) electronic document for Prepared By and Quality signatures.

7) Compliance testing laboratory, location and phone numbers:

Child Related Research, Inc. 448 East Winchester Street Suite 140 Murray, Utah 84107 USA +1 (801) 904-3893	**ifKiV** Institute für Kindersicherheit im Verpackungswesen e.V. Baumeisterstrasse 2 20099 Hamburg Germany +49 40 80 3891	**ivm Institut** VerpackungsMarktforschung GmbH Friedrich-Seele-Str. 20 38122 Braunschweig Germany +49(0)531-28509245	**Perritt Laboratories Inc.** 145 S Main St, Hightstown, NJ 08520, USA +1 (609) 443-4848	**Bird Dog, LLC** 3225 Nolt Road Lancaster PA 17601, USA (717) 881-6602

	Product	NDC	CPSC Regulation to which this product NDC is being certified	Compliance testing laboratory	Date of Testing	CPSIA Exemption Rationale
1	Alecensa® (alectinib) Capsules, 150mg Bottle	50242-130-01	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	ifKiV	May 24, 2004	N/A
2	Boniva Tablets® (ibandronate sodium), 150mg Blister	0004-0186-83	16 CFR § 1700.20(ii)	N/A	N/A	Special packaging is not required due to Boniva® 150mg tablets are below established limits for causing serious personal injury or serious illness.
3	CellCept® Oral Suspension (mycophenolate mofetil for oral suspension) Bottle	0004-0261-29	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	Perritt Laboratories Inc.	September 8, 1998	N/A
4	COTELLIC® (cobimetnib) 20mg Tablet, 63 count Bottle	50242-717-01	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	ifKiV	October 28, 2011	N/A
5	ERIVEDGE® (vismodegib) Capsules, 150mg Bottle	50242-140-01	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	a) Child Related Research, Inc. b) Child Related Research, Inc. c) ivm Institut	a) January 13, 2011 b) September 22, 2006 c) September 28, 2012	N/A
6	Esbriet® (pirfenidone), 267mg Capsule Bottle	50242-121-01	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	Child Related Research, Inc.	September 28, 2015 and January 11, 2016	N/A
7	Esbriet® (pirfenidone), 267mg Tablet Bottle	50242-122-06	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	ifKiV	February 23, 2011	N/A
8	Esbriet® (pirfenidone), 801mg Tablet Bottle	50242-123-01	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	ifKiV	February 23, 2011	N/A
9	Evrysdi® (risdiplam) for oral solution, 60 mg/80 mL (0.75 mg/mL)	50242-175-07	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	ivm Institut	May 31, 2017	N/A
10	GAVRETO® (pralsetinib) 100mg Capsules, 60 ct bottle	50242-210-60	16 CFR § 1700.15 and 16 CFR § 1700.20	Bird Dog, LLC	July 14, 2020	N/A

	Product	NDC	CPSC Regulation to which this product NDC is being certified	Compliance testing laboratory	Date of Testing	CPSIA Exemption Rationale
11	GAVRETO® (pralsetinib) 100mg Capsules, 90 ct bottle	50242-210-90	16 CFR § 1700.15 and 16 CFR § 1700.20	Bird Dog, LLC	July 14, 2020	N/A
12	Klonopin® (clonazepam), 0.5mg, 100 count Bottle	0004-0068-01	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	Child Related Research, Inc.	September 22, 2006	N/A
13	Klonopin® (clonazepam), 1mg, 100 count Bottle	0004-0058-01	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	Child Related Research, Inc.	September 22, 2006	N/A
14	Klonopin® (clonazepam), 2mg, 100 count Bottle	0004-0098-01	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	Child Related Research, Inc.	September 22, 2006	N/A
15	INVIRASE® (saquinavir mesylate) Tablets, 500mg Bottle	0004-0244-51	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	a) Perritt Laboratories Inc. b) ivm Institut	a) April 16, 2003 b) April 1, 2014	N/A
16	Rozlytrek® (entrectinib) Capsules, 100mg Bottle, 30 count	50242-091-30	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	ifKiV	October 28, 2011	N/A
17	Rozlytrek® (entrectinib) Capsules, 200mg Bottle, 90 count	50242-094-90	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	ifKiV	February 23, 2011	N/A
18	TAMIFLU® (oseltamivir phosphate) 30mg Bottle, CDC	0004-0802-08	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	a) Child Related Research, Inc. b) ivm Institut	a) September 22, 2006 b) September 28, 2012	N/A
19	TAMIFLU® (oseltamivir phosphate) 30mg Bottle, DoD	0004-0802-07	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	a) Child Related Research, Inc. b) ivm Institut	a) September 22, 2006 b) September 28, 2012	N/A
20	TAMIFLU® (oseltamivir phosphate) 30mg Bottle, SS	0004-0802-06	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	a) Child Related Research, Inc. b) ivm Institut	a) September 22, 2006 b) September 28, 2012	N/A
21	TAMIFLU® (oseltamivir phosphate) 45mg Bottle, CDC	0004-0801-08	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	a) Child Related Research, Inc. b) ivm Institut	a) September 22, 2006 b) September 28, 2012	N/A

	Product	NDC	CPSC Regulation to which this product NDC is being certified	Compliance testing laboratory	Date of Testing	CPSIA Exemption Rationale
21	TAMIFLU® (oseltamivir phosphate) 45mg Bottle, DoD	0004-0801-07	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	a) Child Related Research, Inc. b) ivm Institut	a) September 22, 2006 b) September 28, 2012	N/A
22	TAMIFLU® (oseltamivir phosphate) 45mg Bottle, SS	0004-0801-06	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	a) Child Related Research, Inc. b) ivm Institut	a) September 22, 2006 b) September 28, 2012	N/A
23	TAMIFLU® (oseltamivir phosphate) 75mg Bottle, CDC	0004-0800-08	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	a) Child Related Research, Inc. b) ivm Institut	a) September 22, 2006 b) September 28, 2012	N/A
24	TAMIFLU® (oseltamivir phosphate) 75mg Bottle, DoD	0004-0800-07	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	a) Child Related Research, Inc. b) ivm Institut	a) September 22, 2006 b) September 28, 2012	N/A
25	TAMIFLU® (oseltamivir phosphate) 75mg Bottle, SS	0004-0800-06	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	a) Child Related Research, Inc. b) ivm Institut	a) September 22, 2006 b) September 28, 2012	N/A
26	TAMIFLU® (oseltamivir phosphate) for oral suspension, 300mg, 6mg/ml Bottle	0004-0822-05	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	ifKiV	May 6, 2010	N/A
27	Tamiflu (R) (oseltamivir phosphate), 75mg, 2x5 blister	0004-0800-85	16 CFR § 1700.14	Perritt Laboratories Inc.	Nov 6, 1998	N/A
28	Tamiflu (R) (oseltamivir phosphate), 45mg, 2x5 blister	0004-0801-85	16 CFR § 1700.14	Perritt Laboratories Inc.	Nov 6, 1998	N/A
29	Tamiflu (R) (oseltamivir phosphate), 30mg, 2x5 blister	0004-0802-85	16 CFR § 1700.14	Perritt Laboratories Inc.	Nov 6, 1998	N/A
30	VALCYTE® (valganciclovir hydrochloride) Tablets, 450mg Bottle	0004-0038-22	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	IVM Institute	September 28, 2012	N/A
31	VALCYTE® (valganciclovir hydrochloride) for oral solution, 50mg/1ml Bottle	0004-0039-09	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	Child Related Research, Inc.	January 12, 2009	N/A

	Product	NDC	CPSC Regulation to which this product NDC is being certified	Compliance testing laboratory	Date of Testing	CPSIA Exemption Rationale
32	XELODA® (capecitabine), 150mg Tablets, 60 count Bottle	0004-1100-20	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	Child Related Research, Inc.	September 22, 2006	N/A
33	XELODA® (capecitabine), 500mg Tablets. 120 count Bottle	0004-1101-50	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	Perritt Laboratories Inc.	November 11, 1998	N/A
34	XENICAL® (orlistat) Capsules, 120mg Bottle	0004-0257-52	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	Perritt Laboratories Inc.	November 11, 1998	N/A
35	Xofluza® (baloxavir marboxil), 40mg (2x 20mg tablets) Blister	50242-828-02	16 CFR § 1700.20	N/A	N/A	Special packaging is not required due to two Xofluza™ 20mg tablets are below established limits for causing serious personal injury or serious illness
36	Xofluza® (baloxavir marboxil), 80mg (4x 20mg tablets) Blister	50242-828-04	16 CFR § 1700.20	Child Related Research, Inc.	August 9, 2018	N/A
37	Xofluza® (baloxavir marboxil), 40mg (1x 40mg tablet) Blister	50242-860-01	16 CFR § 1700.20	N/A	N/A	Special packaging is not required due to one Xofluza™ 40mg tablet is below established limits for causing serious personal injury or serious illness
38	Xofluza® (baloxavir marboxil), 80mg (2x 40mg tablets) Blister	50242-860-02	16 CFR § 1700.20	Child Related Research, Inc.	August 8, 2018	N/A
39	Xofluza® (baloxavir marboxil), 80mg (1x 80mg tablets) Blister	50242-877-01	16 CFR § 1700.20	Child Related Research, Inc.	November 17, 2020	N/A
40	Xofluza® (baloxavir marboxil), for oral suspension, 40 mg/20 mL (2 mg/mL)	50242-583-01	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	IVM Institut	May 31, 2017	N/A
41	ZELBORAF® (vemurafenib) Tablets, 240mg, 112 count Bottle	50242-090-02	16 CFR § 1700.14(a)(10) and 16 CFR § 1700.15	ifKiV	February 23, 2011	N/A

Change History

Version	Description of Change	Other Documents Affected
1.0	New document	N/A
2.0	Added three solid dose Tamiflu (Line 27-29) into the list Added Roche Confidential footer Reformatted throughout to fit into Veeva QualityDocs margins	N/A

Document Approvals

WF Task Approval Verdict: Approve	Adrian Leuenberger(leuenbea), (leuenbea@roche.com) Document Approval 27-Oct-2023 07:05:12 GMT+0000

WF Task Approval Verdict: Approve	Cathy Zhao (ZHAOX88), (zhao.cathy@roche.com) Author Approval 27-Oct-2023 12:17:21 GMT+0000

WF Task Approval Verdict: Approve	Stanley Shimizu(shimizs3), (shimizs3@roche.com) Quality Approval 27-Oct-2023 15:21:34 GMT+0000